Introduction For decades, lung cancer has been closely associated with smoking. While tobacco use remains the leading cause of the disease, it is a common misconception that only smokers develop lung cancer. In reality, thousands of people who have never smoked are diagnosed with lung cancer every year. Research has shown that factors such as […]
Introduction When people hear the words lung cancer, smoking is often the first thing that comes to mind. While smoking remains the leading risk factor, it is not the only cause of lung cancer. In recent years, doctors and researchers have observed an increasing number of lung cancer cases among people who have never smoked.
Introduction For patients diagnosed with EGFR-mutated non-small cell lung cancer (NSCLC), Osimertinib has become one of the most important targeted therapies available today. It is widely prescribed as a first-line treatment for eligible patients and for certain patients whose cancer has developed resistance after earlier EGFR therapies. One of the most common questions patients ask
Generic Osimertinib vs Brand Tagrisso®: Full 2026 Cost Comparison Read More »
Introduction For patients diagnosed with EGFR-mutated non-small cell lung cancer (NSCLC), timely access to prescribed medicines such as Osimertinib can make a significant difference in treatment continuity. However, access to Osimertinib varies widely across countries. Some nations experience delayed product launches, medicine shortages, or regulatory limitations that make obtaining treatment challenging. India has become one
Osimertinib Exporter India: How International Orders Work Read More »
Introduction The treatment of lung cancer has changed dramatically over the past decade. Instead of relying solely on chemotherapy, many patients with non-small cell lung cancer (NSCLC) can now benefit from targeted therapies that are designed to attack specific genetic mutations within cancer cells. While these medicines have improved survival and quality of life for
Lung Cancer Targeted Therapy Cost in India (2026): What Patients Need to Know Read More »
Introduction For many patients diagnosed with EGFR-mutated non-small cell lung cancer (NSCLC), receiving a prescription for Osimertinib is only the beginning of their journey. In several countries, the medicine may not yet be commercially available, may face supply shortages, or may be beyond the financial reach of many patients. Over the years, CBMeds, a division
CBMeds Patient Stories: Accessing Osimertinib Worldwide Read More »
Introduction The treatment of EGFR-mutated non-small cell lung cancer (NSCLC) has evolved significantly over the past two decades. Targeted therapies known as EGFR inhibitors have transformed patient outcomes by specifically blocking cancer cells with EGFR mutations while minimizing damage to healthy cells. Among the most commonly used EGFR inhibitors are Erlotinib, Gefitinib, and Osimertinib. While
EGFR Inhibitors Comparison: Erlotinib vs Gefitinib vs Osimertinib Read More »
Having lung cancer surgery can bring enormous relief—and then a new set of questions. If your oncologist has recommended osimertinib after surgery, you may wonder: If the tumour was removed, why do I need more treatment? Does this mean the cancer is still there? How much will it help? Osimertinib is a targeted anti-cancer medicine.
Osimertinib After Lung Cancer Surgery: What Patients Ask About Adjuvant Therapy Read More »
Introduction Receiving a lung cancer diagnosis can be overwhelming. For many patients, the next challenge is not choosing a treatment—it’s finding access to the medicine their oncologist has prescribed. In many parts of the world, targeted lung cancer medicines may not yet be available, may be temporarily out of stock, or may be priced beyond
Lung Cancer Medicine Access for International Patients: A Complete Guide Read More »
Introduction The treatment landscape for non-small cell lung cancer (NSCLC) has changed dramatically over the past decade. For patients whose tumors carry specific EGFR (Epidermal Growth Factor Receptor) mutations, targeted therapies have significantly improved survival and quality of life compared with traditional chemotherapy. Among these targeted treatments, Osimertinib has become the preferred first-line treatment for
Osimertinib NSCLC First-Line Treatment: A Complete Patient Guide Read More »
